A Phase II Evaluation of Docetaxel (NSC628503) Plus Trabectedin (Yondelis; R279741, IND Pending) With Growth Factor Support in the Third-Line Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Trial Profile

A Phase II Evaluation of Docetaxel (NSC628503) Plus Trabectedin (Yondelis; R279741, IND Pending) With Growth Factor Support in the Third-Line Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2012

At a glance

  • Drugs Docetaxel (Primary) ; Trabectedin (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Jul 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
    • 24 Jan 2012 Planned End Date (1 Jul 2014) added as reported by ClinicalTrials.gov.
    • 09 Jun 2010 Data from this study will be reported at the annual meeting of the American Society of Clinical Oncology (ASCO 2010), according to a PharmaMar media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top